Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report

Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivola, Miriam, Arienti, Vincenzo, Bassetti, Nicola, Civardi, Serena, Brondino, Natascia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150017/
https://www.ncbi.nlm.nih.gov/pubmed/35651653
http://dx.doi.org/10.17179/excli2022-4694
_version_ 1784717332797456384
author Olivola, Miriam
Arienti, Vincenzo
Bassetti, Nicola
Civardi, Serena
Brondino, Natascia
author_facet Olivola, Miriam
Arienti, Vincenzo
Bassetti, Nicola
Civardi, Serena
Brondino, Natascia
author_sort Olivola, Miriam
collection PubMed
description Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.
format Online
Article
Text
id pubmed-9150017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Leibniz Research Centre for Working Environment and Human Factors
record_format MEDLINE/PubMed
spelling pubmed-91500172022-05-31 Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report Olivola, Miriam Arienti, Vincenzo Bassetti, Nicola Civardi, Serena Brondino, Natascia EXCLI J Case Report Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. Leibniz Research Centre for Working Environment and Human Factors 2022-02-28 /pmc/articles/PMC9150017/ /pubmed/35651653 http://dx.doi.org/10.17179/excli2022-4694 Text en Copyright © 2022 Olivola et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Case Report
Olivola, Miriam
Arienti, Vincenzo
Bassetti, Nicola
Civardi, Serena
Brondino, Natascia
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title_full Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title_fullStr Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title_full_unstemmed Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title_short Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
title_sort use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150017/
https://www.ncbi.nlm.nih.gov/pubmed/35651653
http://dx.doi.org/10.17179/excli2022-4694
work_keys_str_mv AT olivolamiriam useofintranasalesketamineinagirlwithtreatmentresistantdepressionandautismspectrumdisordersacasereport
AT arientivincenzo useofintranasalesketamineinagirlwithtreatmentresistantdepressionandautismspectrumdisordersacasereport
AT bassettinicola useofintranasalesketamineinagirlwithtreatmentresistantdepressionandautismspectrumdisordersacasereport
AT civardiserena useofintranasalesketamineinagirlwithtreatmentresistantdepressionandautismspectrumdisordersacasereport
AT brondinonatascia useofintranasalesketamineinagirlwithtreatmentresistantdepressionandautismspectrumdisordersacasereport

Ejemplares similares